Edge Pharma, LLC recalls Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%
Recalled February 2, 2022 · FDA recall D-0404-2022 · Edge Pharma
Hazard
Lack of Assurance of Sterility · FDA Class II
Units
1202 syringes
Sold at
nationwide
Description
Lack of Assurance of Sterility
Product
Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18
Manufacturer(s)
Edge Pharma, LLC
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →